More disappointment for Orphazyme as FDA rejects Niemann Pick C application

The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.

Photo: Orphazyme/PR

The bad news just keeps on coming for Orphazyme.

The biotech company's key candidate, arimoclomol, got the thumbs down from the US Food and Drug Administration (FDA) as a treatment for Niemann Pick type C, also known as NPC.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs